{"links":{"feed":"https://www.erudio.com/reports/panku-lung01-nct06382116/feed.json","html":"https://www.erudio.com/reports/panku-lung01-nct06382116","json":"https://www.erudio.com/reports/panku-lung01-nct06382116.json","markdown":"https://www.erudio.com/reports/panku-lung01-nct06382116.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"panku-lung01-06382116"}},"request":"https://www.erudio.com/contact?report=panku-lung01-06382116"},"offer":{"cited_clinicians":18,"cited_commentary_sources":35,"verified_hcp_statements":97,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified speaker identities: the verified IDs of the people in the report, led by the NPI or their institution's staff page, so a Medical Affairs team can check that each statement is attributed to the right person: also X, Bluesky, LinkedIn and other web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For checking attribution inside the organization; never for outreach to or targeting of clinicians. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":20,"optional":true,"price_per_verified_person_usd":15,"price_usd":300,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"panku-lung01-nct06382116"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=panku-lung01-06382116","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/panku-lung01-nct06382116","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 97 verified statements · 55 from 18 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need at least 5 confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); with fewer, a report is sold one size down.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-04T12:49:36.446871Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":27,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":25,"title":"Primary endpoint: Progression-free survival (PFS)"},{"claim_count":23,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":21,"title":"Secondary endpoints"},{"claim_count":12,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":23,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":16,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":2,"title":"Patient-valued benefit and missing quality-of-life evidence"},{"claim_count":12,"coverage":"discussed","id":"A2","source_count":6,"title":"Global translatability and contemporary prior treatment"},{"claim_count":10,"coverage":"discussed","id":"A3","source_count":8,"title":"Post-TKI sequencing and biomarker-directed alternatives"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":4,"title":"Targeting, payload contribution and predictive biomarkers"},{"claim_count":2,"coverage":"discussed","id":"A5","source_count":2,"title":"Brain metastases and intracranial efficacy"},{"claim_count":3,"coverage":"discussed","id":"A6","source_count":2,"title":"Diagnostic feasibility, affordability and routine-care access"},{"claim_count":21,"coverage":"discussed","id":"A7","source_count":16,"title":"Development outlook and geography-specific treatment positioning"}],"counts":{"cited_clinicians":18,"cited_clinicians_by_role":{"physician":2,"physician, Medical oncology":16},"cited_physicians":18,"cited_sources":36,"claims_by_expression_type":{"comparison":6,"experience":1,"interpretation":24,"opinion":24,"primary_context":5,"question":6,"restatement":20,"uncertainty":7,"unspecified":4},"claims_by_kind":{"interpretation":1,"publication_statement":4,"source_observation":92},"clinician_statements":55,"evidence_units":56,"findings":8,"organisational_accounts":8,"people_cited":24,"people_identity_verified":20,"people_total":25,"screened_sources":91,"verified_claims":97},"findings_index":[{"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":6},"has_counterview":true,"limitations":2,"links":{"context":0,"support":11},"ma_question":true,"named_voices":4,"passages":6,"sources":6,"sources_by_kind":{"commentary":5,"publication":1}},"title":"One clinician thinks iza-bren looks like a new standard and would like to use it; others qualify their enthusiasm"},{"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":4,"views":5},"has_counterview":true,"limitations":3,"links":{"context":3,"support":11},"ma_question":true,"named_voices":5,"passages":9,"sources":7,"sources_by_kind":{"commentary":5,"media":1,"publication":1}},"title":"Clinicians flag toxicity and dose-management burden; an episode asks whether the gain is worth it"},{"id":"F3","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":3,"views":4},"has_counterview":true,"limitations":2,"links":{"context":1,"support":14},"ma_question":true,"named_voices":8,"passages":13,"sources":11,"sources_by_kind":{"commentary":9,"media":1,"publication":1}},"title":"Clinicians keep OS provisional, despite one relayed description of improved survival"},{"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":6,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Clinicians seek global validation; one challenges the chemotherapy-only comparator"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":5,"restated":0,"views":3},"has_counterview":true,"limitations":2,"links":{"context":1,"support":10},"ma_question":true,"named_voices":7,"passages":8,"sources":7,"sources_by_kind":{"commentary":7}},"title":"Clinicians see no settled best sequence among expanding post-TKI options"},{"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":6},"has_counterview":false,"limitations":3,"links":{"context":3,"support":7},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Clinicians seek better selection; a discussion leaves targeting versus payload unresolved"},{"id":"F7","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"One clinician says diagnostic difficulty and affordability constrain actual treatment choices"},{"id":"F8","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":7},"has_counterview":true,"limitations":2,"links":{"context":1,"support":12},"ma_question":true,"named_voices":6,"passages":8,"sources":8,"sources_by_kind":{"commentary":7,"publication":1}},"title":"Clinicians see an encouraging read-through to global iza-bren development"}],"medical_affairs_question":"What combination of mature survival, patient-reported benefit, feasible toxicity management and contemporary comparative evidence would make iza-bren a usable option in a particular health system?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Clinical readiness: enthusiasm does not mean the same thing to every clinician"},{"id":"section-2","level":2,"title":"Tolerability: low discontinuation does not settle the value question"},{"id":"section-3","level":2,"title":"Survival: preserve the favorable trend and its interim limitation together"},{"id":"section-4","level":2,"title":"Applicability: geography, prior therapy and the control arm are distinct problems"},{"id":"section-5","level":2,"title":"Sequencing: an expanding menu is not a ranked algorithm"},{"id":"section-6","level":2,"title":"Selection and mechanism: attractive hypotheses are not validated rules"},{"id":"section-7","level":2,"title":"Routine-care access: the usable menu can be smaller than the evidence menu"},{"id":"section-8","level":2,"title":"Development outlook: encouragement must stay attached to the right program and setting"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-free survival (PFS)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":8},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":5},{"id":"F6","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":9},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-04T12:49:36.446871Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-04T13:04:27Z","record_hash":"8618a8f3022bce15c893af644c90e88db77764d2e827f0ad9b1cd63447fd0d89","release_hash":"1adf2eeb25674eac3e49d2c7c45bd4684a406cb14be79cf3c6be697d03da607c","report_id":"erudio-nct06382116","run_id":"34a86d2f-4cf6-47c8-9c7c-a708fce9bacd","schema_version":"5.0","slug":"panku-lung01-06382116","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PANKU-Lung01 tests whether izalontamab brengitecan (iza-bren) improves progression-free survival versus platinum chemotherapy after EGFR-TKI failure in advanced non-small-cell lung cancer; one clinician would like to use it, while others qualify support. The report cites 18 physicians, including 16 medical oncologists. Debate covers differing interpretations of overall survival and the unsettled order of post-TKI treatments. What combination of mature survival data, patient-reported benefit, workable toxicity management and contemporary comparisons would support local use of iza-bren?","meta_description":"91 sources screened · 97 verified statements (55 from clinicians verified by NPI or staff page) from 36 sources · 8 findings. Updated Nov 4, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-4f6513db43171fab0736"],"id":"F2","paraphrase":"An AI-voiced podcast asks how to weigh progression-free survival against treatment toxicity with iza-bren.","publication_caveats":["The episode uses AI-generated voices, not identifiable clinician interviewees."],"source_channel":"podcast","source_date":"2026-11-02","title":"Clinicians flag toxicity and dose-management burden; an episode asks whether the gain is worth it"},{"cited_claim_ids":["claim-74f4a03d15d00a57e0b1"],"id":"F5","paraphrase":"A physician on LinkedIn asks about sequencing antibody-drug conjugates and biomarker-directed treatment after osimertinib.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"linkedin_post","source_date":"2026-10-26","title":"Clinicians see no settled best sequence among expanding post-TKI options"}]},"publication":{"approved_at":"2026-11-04T13:04:27Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":91},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","3 matching sources (3 YouTube videos) could not be read and are not included.","1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.","Not yet captured in this edition: a view on the range of treatment options after EGFR-TKI failure.","Not yet captured in this edition: a view on the global generalizability of post-EGFR-TKI antibody–drug conjugate evidence from China-only trials.","Not yet captured in this edition: a view on how geographic differences in treatment standards and enrollment complicate future post-EGFR-TKI trial design.","68 passages in 61 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","97 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 41 sources about other trials or topics are not included.","The sources reviewed for this edition are a selected public discussion, not a representative survey of HCPs. Reposts, repeated posts and relays of the same presentation do not establish independent agreement.","Some potentially relevant passages were not fully assessed, three videos could not be read, and name-focused searches may miss unnamed treatment-decision discussions or transcription variants.","The podcast uses AI-generated voices. Its discussion cannot be attributed to a named clinician on the basis of editorial involvement.","Some editorial opinions discussed in the episode are not represented here, which may leave its account of generalizability and future trial design incomplete.","Several authors' clinical roles are unconfirmed or unstated. Account-level commentary and unconfirmed professional identity do not establish clinician testimony or increase the weight of a statement.","OS remains immature in the cited accounts, and the episode reports that quality-of-life data were unavailable. These limits prevent the report from resolving the survival and patient-value questions raised by speakers.","Separate-trial comparisons are not head-to-head evidence. Different safety categories, reported denominators and numerical descriptions are preserved rather than combined.","No full protocol or exact regulatory label was available to resolve every methodological question or verify indication-specific approval language."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":1,"publication":1,"registry":0,"regulatory":0,"x_thread":32,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":35,"context":1},"count":36,"evidence_window":{"end":"2026-11-03","start":"2026-08-19"},"retrieval_snapshot":"2026-11-04T08:02:35.649076Z","timeline":[{"count":6,"week":"2026-W34"},{"count":1,"week":"2026-W43"},{"count":26,"week":"2026-W44"},{"count":2,"week":"2026-W45"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06382116:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06382116:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42933461","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47nm5qperrpmcqdmzxt3qgec-3mz3ngpdays25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mysz57i5rc2o","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7495910104257458176","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520422150378336256","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520452017597718528","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:bf0cb7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089663345406193981:244239b0-8eeb-4764-a5b3-cab4c0b968d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089879779205882297:0f34234a-d557-424a-9db0-6de991802f81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089957500359492090:97db3cfa-0732-489f-8275-1f93ac2ec3ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090066774523806027:4a966b91-a139-45d0-ae31-b8d7e1e673f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090085828311793749:58b046d2-3807-4583-81ed-93c6b21b5b19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090137300319740087:0d5ae697-0f51-4aa0-990a-2e55a927f5bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090139140830413303:14a999b4-7200-41da-a6ea-57c5c5974474","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090144329620664467:85ade868-5693-4abf-b645-23cb468be1de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090154013601771552:9612f97e-caa8-4e80-bdfd-9d4e3900abfe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090414185695854966:2ee2db11-7427-4d17-9dc9-ae5a3bd61226","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090423412531322935:ed13d1c2-8e38-4ed3-a81f-a33e850e30d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090826884892549620:f72dab75-8763-4d67-8bd7-90adb75d4d92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096274387033034956:e97d479e-f028-44c5-b441-16ef6500f2a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099731256485236811:72a3c30e-f708-4949-984a-8177d2a9bf6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099732873100034096:75c7f412-6976-4f3a-9478-d9f71a0e7bb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099735571778490405:f43a7a8d-7564-4dc5-bcbb-7118563708b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102775002819178992:c6eefdf7-3d8d-4f56-852c-7af715ac3584","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104926770810048757:9cad7fd2-ceec-425c-8d6c-5f5eae82231a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105739913681416293:a528d67f-614a-4d55-91b2-f4a541c7473b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106775483614408806:183c626b-de01-48e6-b94a-7516e04215e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107390688413339706:b17c3c31-43b8-41ec-b2a8-c07f203d5227","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109655085940977897:ad3cab0c-5bf9-452e-975d-305717280ded","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112846605963407601:e98c7409-89d3-4dda-90bd-9e9348cefece","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112867869759537359:41c5ee38-f46c-4e70-8695-11399f7c20ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113454214810591712:5bfa86ac-e739-4084-ac59-c06d30b1ab8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113525926671605768:cb88ee34-0946-47a7-9ece-62fe27e06e19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113561393152540999:e27bd256-e61e-4763-849e-50910935d1ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114038371689365546:74291d35-5caf-458f-ab12-0bd923fcba9d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114370585606410361:4c99d9a0-d236-48e0-919a-761e9f3c4dd7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114608171100913921:ada57ae9-3e77-4ae4-9a98-fbdacf949f45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114621099421942026:69081f2c-da00-459f-b63f-08338bc3e925","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114626181219717295:64f91539-b9a5-4350-8244-35091a3c7d8f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114634067530350798:d172a810-2cac-433d-bbe5-82bb9b294e2e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114634556158656762:36ff05c5-aeb3-4adb-b697-00e9e6c50c1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114634747079229822:f3a7127a-7a5a-4de4-82e6-dbf97d2696de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635060494373050:2556caac-a932-4e12-a584-311c6d2603e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635135874167220:311face8-c692-4b09-ab7a-aa1a86f97dd0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635288718856317:75d02ea3-9f01-4f97-8472-c5611829fdb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635678143430846:56a1951d-7433-4168-b100-890e6c3e8e15","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635699425329372:cdb061b2-d25a-469e-b825-2b82dbc058e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635700142317999:92783c88-5f4f-4306-9edc-bbe5cfa0d345","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635939339243937:06156abc-0d31-46fa-bc51-09167038b4df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114636843538895078:52c53645-e64d-4fee-8e9c-57238d1b936a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114637129720500693:bcb6ee13-05b7-469e-82fb-14f8d2abdb79","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114637864986358083:f27716cb-c0d7-4462-a8b9-70665c4330bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114640594823708880:c4292a11-014b-4f2e-ae9f-b17477bdb006","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114643008641441971:6a02e763-87d8-44cd-a766-df6646394c74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114643141995229588:6986eece-4fc3-4cee-9d16-e36cdd15c924","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114644703983390769:6fa27495-472e-4837-a08a-b1c610c683d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114646320807841875:fa60c2d6-92e8-485a-a9df-0d8bf3e2e638","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114701269344354776:f93d021e-e17d-407b-b3bc-f5d22bb9b4e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114711310571094293:7ed81738-fffa-41fd-afb7-8d0ca617e56e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114719626391339484:54c63ce0-286f-4cb0-b7d0-0cd2fe29d060","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114732675793928590:0280be47-f60d-4530-bc9a-0b9b26764a68","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114746335999975781:51906f63-4fcd-4369-b003-c0f8d7394e8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114747009748136062:1b3778bd-8e51-46eb-9648-3b9af8ef00b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114759164287386047:c84d7017-86fb-4f4b-bd7a-6ab768db0488","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114770664846692389:1b0a5809-652e-426e-9fbb-e23ecc0e4bd2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114801891200901251:aa959297-e60f-4917-a838-fa4e9a04dd6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114836131946590705:731a55dc-81c6-4dae-9842-4b5ae29a03ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114838033493016642:749533dd-ff73-42b0-a7fe-03adf86688db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114842778471420333:2158e4c6-38f9-4b41-b6f2-6424835c1619","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114863795214454931:08e6324d-21d0-4818-998d-55813f4ee939","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114881304479084971:78ebb6dc-bc3b-45a5-8245-dca8bd654ddf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114929179225694551:4f1809c2-8aa0-4b8d-9e8f-e2308e0a0804","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115008286714142859:6816f901-d825-4a6e-920e-cbc0427c119a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115017303113056315:447b4a7e-d760-4427-bc13-2c915ba3d7e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115071914452369796:38ad5045-f738-48d4-bd5e-18674f61407f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115093109671657948:cbaad163-e09c-4289-95dc-d1c1c1f78053","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115115309531041990:81e86c62-6f04-481f-880f-090167512a42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115121854436327897:f8ce5caa-4c7f-49b3-8eb0-249029a92e51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115255522429706241:e98f6964-b6dc-4e22-91d2-1c136711eb32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115338001534402792:d6726fce-a759-4b78-8d7c-125e23a9cc72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115360089381175731:5d4a582a-8791-49e2-a1c0-89fc19c6bac2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115405801678323998:67ef217e-4f18-4083-9186-d22703b255c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115519016798417364:e2d6f3a0-536b-440d-b9f5-66cb8287885a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115736322581385315:80ef9e72-23ab-492b-b81d-93137aa60328","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115740190689923145:6ce89b34-fd91-4024-881b-d5c532755875","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115740488250863697:d58bb93e-d465-4c05-8b75-57806af39da6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115847362539344304:dcd183aa-8aa8-4bca-a601-c1660ea50fd9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115859675023315400:1d6c9f0a-87a3-4081-8c3b-879b3da0c461","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116125688780714095:9e05c3a2-9c0a-47ad-8abe-1b965aad6871","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116495141376606578:72cff74b-e745-4adc-980e-2e288a7c8af7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116584722365129010:2d07868e-1bb5-4094-af3c-b9d7ae3024fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117622376737513635:ba4e70fd-8b48-4127-bb6d-5d324ce21235","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":3,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":85,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":91},"count":91,"evidence_window":{"end":"2026-11-03","start":"2026-08-18"},"retrieval_snapshot":"2026-11-04T08:02:35.649076Z","timeline":[{"count":13,"week":"2026-W34"},{"count":1,"week":"2026-W36"},{"count":3,"week":"2026-W38"},{"count":1,"week":"2026-W39"},{"count":3,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":7,"week":"2026-W43"},{"count":59,"week":"2026-W44"},{"count":2,"week":"2026-W45"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: bl-b01d1","status":"unmapped"},{"reason":"Unmapped registry intervention: pemetrexed+cisplatin or carboplatin","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"PANKU-Lung01","aliases":["PANKU-Lung01","A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure"],"brief_title":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","collaborators":["Baili-Bio (Chengdu) Pharmaceutical Co., Ltd."],"conditions":["Non-small Cell Lung Cancer"],"display_condition":"EGFR-mutated advanced non-small-cell lung cancer after EGFR-TKI failure","display_interventions":[["izalontamab brengitecan (BL-B01D1)"]],"enrollment":{"count":432,"type":"ACTUAL"},"interventions":[{"name":"BL-B01D1","synonyms":["iza-bren","izalontamab brengitecan","BMS-986507"],"type":"DRUG"},{"name":"Pemetrexed+Cisplatin or Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06382116","official_title":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-08","type":"ESTIMATED"},"primary_endpoints":[{"description":"Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.","measure":"Progression-free survival (PFS)","timeFrame":"Up to approximately 24 months"}],"registered_date":{"date":"2024-04-24","type":"ACTUAL"},"registry_last_updated":"2026-07-23","registry_url":"https://clinicaltrials.gov/study/NCT06382116","short_name":"PANKU-Lung01","short_name_basis":"canonical_name","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","start_date":{"date":"2024-05-22","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"BL-B01D1-301","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}